Why Is Everyone Talking About Moderna Stock?
Right now, nearly everyone in the healthcare investment world -- and perhaps in the general investment world -- is talking about Moderna (NASDAQ: MRNA). The biotech, which is developing a potential COVID-19 vaccine, has returned nearly 380% to investors since October 2019. That gives the company a $27 billion valuation less than two years after its IPO in late 2018.
With Moderna stock as high as it is, current investors are thinking about taking profits, while new investors are contemplating whether or not the stock will soon see a severe correction. As it turns out, plenty of great stocks have a habit of never seeming "cheap" as soon as they get the ball rolling, and enjoy a continued momentum. Today, let's take a look at why Moderna's rally is probably far from over.
Image source: Getty Images.
Source Fool.com